As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:
6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -4.55 -4.55 |
37%
37%
|
|
| EBIT (Operating Income) EBIT | -4.56 -4.56 |
37%
37%
|
|
| Net Profit | -4.71 -4.71 |
15%
15%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Mr. Chay |
| Employees | 4 |
| Founded | 1992 |
| Website | www.titanpharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


